Philips announces FDA clearance for its AlluraClarity interventional X-ray system

  Philips announces FDA clearance for its AlluraClarity interventional X-ray
                                    system

- Philips' AlluraClarity system with ClarityIQ technology provides high
quality imaging for a comprehensive range of clinical procedures

- Low X-ray dose settings help clinicians to manage radiation exposure

PR Newswire

ANDOVER, Mass., July 3, 2013

ANDOVER, Mass., July 3, 2013 /PRNewswire/ --Royal Philips (NYSE: PHG, AEX:
PHIA) today announced that it has received 510(k) clearance from the US Food
and Drug Administration (FDA) to market its innovative AlluraClarity live
image guidance system in the US.

To view the multimedia assets associated with this release, please click
http://www.prnewswire.com/news-releases/philips-announces-fda-clearance-for-its-alluraclarity-interventional-x-ray-system-214083751.html

In close collaboration with leading clinicians in the field of
minimally-invasive medicine, Philips has been driving innovation in
interventional imaging for more than 50 years, helping to guide procedures
such as the catheter-based treatment of obstructed coronary arteries, brain
aneurysms, heart rhythm disorders and defective heart valves (heart valve
replacement).

Philips' AlluraClarity system with its powerful ClarityIQ technology provides
high quality imaging for a comprehensive range of clinical procedures,
achieving excellent visibility at low X-ray dose levels for patients of all
sizes. To reflect the cost pressures that modern hospitals and health systems
face, ClarityIQ technology will also be available as an upgrade for the
majority of Philips' installed base of monoplane and biplane interventional
X-ray systems.

"All patients treated via X-ray guided interventions benefit from the
advantage of low radiation exposure, but it is especially important when you
are treating patients who have to undergo lengthy and complex procedures,"
said Dr. Marco van Strijen, interventional radiologist at the St. Antonius
Hospital Utrecht/Nieuwegein, the Netherlands. "We have been using Philips'
AlluraClarity system for more than a year now and have really grown to
appreciate the low dose settings. This technology is making a difference where
it really matters."

"The transition from highly invasive surgical procedures to minimally-invasive
image-guided therapies, with all their intrinsic patient benefits, is a
transformation in the delivery of healthcare that is rapidly accelerating
around the globe," said Gene Saragnese, CEO Imaging Systems at Philips
Healthcare. "It is an area where technology innovation and procedure
innovation go hand in hand. AlluraClarity is a perfect example of how Philips'
close collaboration with clinical partners has combined these two areas of
innovation to facilitate more advanced treatment while at the same time
managing radiation dose."

AlluraClarity's low X-ray dose settings are a radical new development in the
healthcare industry that will help clinicians to better manage their patients'
and their own exposure to X-ray radiation. This achievement is the result of a
multi-year development program that formed part of Philips' continuous
investment in healthcare R&D, totaling EUR 803 million in 2012.

Philips' AlluraClarity was commercially introduced outside the US in mid-2012,
and since then more than 200 systems have been ordered. With this important
milestone of FDA clearance, the system can now be marketed in the world's
largest healthcare market. For more information on Philips' AlluraClarity,
please visit www.philips.us/AlluraClarity.

For further information, please contact:

Rachel Bloom-Baglin
Philips Healthcare
Tel.: +1 978 7609007
E-mail: rachel.bloom-baglin@philips.com

Steve Klink
Philips Corporate Communications
Tel.: +31 6 10888824
E-mail: steve.klink@philips.com

About Royal Philips:
Royal Philips (NYSE: PHG, AEX: PHIA) is a diversified health and well-being
company, focused on improving people's lives through meaningful innovation in
the areas of Healthcare, Consumer Lifestyle and Lighting. Headquartered in the
Netherlands, Philips posted 2012 sales of EUR 24.8 billion and employs
approximately 116,000 employees with sales and services in more than 100
countries. The company is a leader in cardiac care, acute care and home
healthcare, energy efficient lighting solutions and new lighting applications,
as well as male shaving and grooming and oral healthcare. News from Philips is
located at www.philips.com/newscenter.

SOURCE Royal Philips

Website: http://www.philips.com/newscenter
 
Press spacebar to pause and continue. Press esc to stop.